Syros Pharmaceuticals, Inc. (SYRS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Syros Pharmaceuticals, Inc. (SYRS) trades at $0.00 with AI Score 53/100 (Grade B). Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control. Market cap: $2,683, Sector: Healthcare.
Last analyzed: May 4, 2026Analyst Coverage for SYRS: SYRS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYRS against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SYRS: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
Syros Pharmaceuticals, Inc. (SYRS) Healthcare & Pipeline Overview
Syros Pharmaceuticals, Inc., a clinical-stage biotechnology company, is dedicated to pioneering gene control medicines for cancer and monogenic diseases. Their pipeline features Tamibarotene, SY-2101, and SY-5609, addressing significant unmet needs in myelodysplastic syndrome, acute promyelocytic leukemia, and advanced solid tumors, positioning them within a competitive biotech landscape.
What Is the Investment Thesis for SYRS?
Syros Pharmaceuticals presents a high-risk, high-reward investment profile typical of clinical-stage biotech companies. The primary value driver is the successful development and commercialization of Tamibarotene, particularly for the treatment of myelodysplastic syndrome (MDS). Positive Phase III trial results and subsequent regulatory approval could significantly increase the company's valuation. The advancement of SY-2101 and SY-5609 through clinical trials represents additional upside potential. However, the company's negative profit margin of -1656.3% underscores its reliance on external funding and the inherent risks associated with drug development, including clinical trial failures and regulatory hurdles. The company's gross margin is 77.3%.
Based on FMP financials and quantitative analysis
SYRS Key Highlights
- Syros Pharmaceuticals is focused on gene control medicines for cancer and monogenic diseases.
- Tamibarotene, a selective retinoic acid receptor alpha agonist, is in Phase III clinical trial for myelodysplastic syndrome.
- SY-2101, a novel oral form of arsenic trioxide, is being developed for acute promyelocytic leukemia.
- SY-5609, a cyclin-dependent kinase 7 inhibitor, is in a Phase I clinical trial for advanced solid tumors.
- The company has a gross margin of 77.3%.
Who Are SYRS's Competitors?
SYRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| ANAB AnaptysBio, Inc. | $54.24 | +4.11% | $2.34B | 79 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
| SLGL Sol-Gel Technologies Ltd. | $75.30 | +2.45% | $211.58M | 68 |
| PRVB Provention Bio, Inc. | $24.98 | +0.00% | $2.38B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYRS's Key Strengths?
- Proprietary gene control technology platform.
- Clinical-stage pipeline with multiple drug candidates.
- Strategic collaborations with Incyte and TMRC.
- Experienced management team.
What Are SYRS's Weaknesses?
- High reliance on clinical trial success.
- Significant financial risk due to negative profit margin.
- Limited commercialization experience.
- Dependence on external funding.
What Could Drive SYRS Stock Higher?
- Phase III clinical trial results for Tamibarotene in myelodysplastic syndrome.
- Advancement of SY-2101 through clinical development for acute promyelocytic leukemia.
- Development of SY-5609 for select advanced solid tumors.
- Collaboration with Incyte Corporation to identify therapeutic targets for myeloproliferative neoplasms.
- Potential milestone payments and royalties from TMRC Co. Ltd. for tamibarotene.
What Are the Key Risks for SYRS?
- Clinical trial failures for Tamibarotene, SY-2101, or SY-5609.
- Regulatory hurdles and delays in obtaining drug approvals.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Dependence on external funding to support research and development activities.
- Risks associated with trading on the OTC market, including limited liquidity and disclosure.
What Are the Growth Opportunities for SYRS?
- Growth opportunity 1: Successful completion of the Phase III clinical trial for Tamibarotene in myelodysplastic syndrome (MDS) represents a significant growth catalyst. Positive results could lead to regulatory approval and commercialization, addressing a substantial unmet need in a genomically defined subset of MDS patients. The market for MDS treatments is projected to reach billions of dollars, offering a substantial revenue opportunity for Syros. The timeline for potential approval is contingent on trial outcomes and regulatory review, but could occur within the next 2-3 years.
- Growth opportunity 2: Advancing SY-2101, a novel oral form of arsenic trioxide, through clinical development for acute promyelocytic leukemia (APL) offers another growth avenue. If successful, SY-2101 could provide a more convenient and potentially safer treatment option for APL patients. The APL market, while smaller than MDS, still represents a valuable opportunity for Syros. The timeline for SY-2101's development depends on clinical trial progress, with potential for market entry in the coming years.
- Growth opportunity 3: The development of SY-5609, a cyclin-dependent kinase 7 (CDK7) inhibitor, for select advanced solid tumors presents a longer-term growth opportunity. CDK7 inhibition is a promising approach in cancer therapy, and positive Phase I trial results could pave the way for further clinical development and potential partnerships. The market for solid tumor treatments is vast, offering significant potential for Syros if SY-5609 proves effective and safe. The timeline for this program is likely several years, given its early stage of development.
- Growth opportunity 4: Syros's collaboration with Incyte Corporation to identify therapeutic targets for myeloproliferative neoplasms (MPNs) could yield new drug candidates and expand the company's pipeline. This partnership provides access to Incyte's expertise and resources, potentially accelerating the discovery and development of novel MPN therapies. The MPN market is growing, driven by increasing prevalence and advancements in treatment options. The timeline for this collaboration is ongoing, with potential for new drug candidates to emerge in the coming years.
- Growth opportunity 5: The license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene could generate revenue through royalties and milestone payments. This agreement expands the geographic reach of tamibarotene and provides Syros with additional financial resources to support its other programs. The timeline for revenue generation depends on TMRC's progress in developing and commercializing tamibarotene in their respective territories.
What Opportunities Does SYRS Have?
- Successful commercialization of Tamibarotene.
- Expansion of pipeline through internal development and collaborations.
- Potential for breakthrough therapies in cancer and monogenic diseases.
- Growing market for targeted therapies.
What Threats Does SYRS Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Patent challenges.
What Are SYRS's Competitive Advantages?
- Proprietary gene control technology.
- Clinical-stage pipeline of drug candidates.
- Intellectual property protection for its drug candidates.
- Strategic collaborations with leading pharmaceutical companies.
What Does SYRS Do?
Syros Pharmaceuticals, Inc., founded in 2011 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases. The company aims to control genes to treat diseases. Syros's lead product candidate is Tamibarotene, a selective retinoic acid receptor alpha agonist, currently in Phase III clinical trial for a genomically defined subset of patients with myelodysplastic syndrome (MDS) and Phase II clinical trial for patients with acute myeloid leukemia (AML). Another key asset is SY-2101, a novel oral form of arsenic trioxide, intended for treating patients with acute promyelocytic leukemia (APL). Additionally, SY-5609, a cyclin-dependent kinase 7 (CDK7) inhibitor, is in a Phase I clinical trial for patients with select advanced solid tumors. Syros has also established collaborations to expand its research and development efforts. This includes a target discovery, research collaboration, and option agreement with Incyte Corporation, focused on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. Formerly known as LS22, Inc., Syros Pharmaceuticals, Inc. changed its name in August 2012, marking a new chapter in its commitment to gene control medicines.
What Products and Services Does SYRS Offer?
- Develop gene control medicines for cancer and monogenic diseases.
- Conduct clinical trials for Tamibarotene in myelodysplastic syndrome and acute myeloid leukemia.
- Develop SY-2101, an oral form of arsenic trioxide, for acute promyelocytic leukemia.
- Develop SY-5609, a CDK7 inhibitor, for advanced solid tumors.
- Collaborate with Incyte Corporation to identify therapeutic targets for myeloproliferative neoplasms.
- License tamibarotene to TMRC Co. Ltd. for development and commercialization.
How Does SYRS Make Money?
- Develop and commercialize proprietary drug candidates.
- Generate revenue through product sales upon regulatory approval.
- Establish collaborations and licensing agreements to expand research and development efforts.
- Receive milestone payments and royalties from partners.
What Industry Does SYRS Operate In?
Syros Pharmaceuticals operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant financial risk. The market for cancer and monogenic disease treatments is substantial and growing, driven by an aging population and advancements in genomic medicine. Competition is fierce, with numerous companies pursuing similar therapeutic targets. Syros differentiates itself through its focus on gene control medicines and its pipeline of clinical-stage assets. The company's success depends on its ability to navigate the complex regulatory landscape and secure funding to advance its programs.
Who Are SYRS's Key Customers?
- Patients with cancer and monogenic diseases.
- Healthcare providers who prescribe and administer Syros's therapies.
- Pharmaceutical companies through collaborations and licensing agreements.
- Research institutions involved in clinical trials and drug development.
SYRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Syros has been generating significant buzz in the community lately, with many highlighting the potential of their pipeline targeting hematologic malignancies.
- Recent insider buying activity suggests that those with the closest view of the company see value at these levels, which is always encouraging.
- There's a growing perception that Syros is undervalued given the progress of their clinical trials and potential market opportunities.
- Positive whispers around potential partnerships or collaborations are circulating within the community, fueling optimism.
Bear Case
- Despite the pipeline's potential, the community is also wary of the inherent risks in biotech, especially concerning clinical trial outcomes.
- The overall market sentiment towards smaller biotech companies has been cautious recently, potentially impacting Syros's stock performance.
- Some are concerned about the company's cash runway and the potential need for future dilutive financing.
- There's a lingering skepticism regarding the commercial viability of Syros's products, even if clinical trials are successful.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SYRS Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Mar 12, 2025
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Mar 12, 2025
-
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
benzinga · Mar 11, 2025
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Dec 19, 2023
SYRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYRS.
Price Targets
Wall Street price target analysis for SYRS.
SYRS MoonshotScore
What does this score mean?
The MoonshotScore rates SYRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
12 Health Care Stocks Moving In Tuesday's After-Market Session
Leadership: James E. Bradner
Unknown
Information about James E. Bradner's background is not available in the provided data. Therefore, I am unable to provide details regarding his career history, education, previous roles, or credentials. Without access to this information, I cannot accurately portray his professional journey and qualifications.
Track Record: Information about James E. Bradner's track record is not available in the provided data. Therefore, I am unable to provide details regarding his key achievements, strategic decisions, or company milestones under his leadership. Without access to this information, I cannot accurately portray his professional accomplishments and impact on the company.
SYRS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Syros Pharmaceuticals may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier often implies a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to less stringent listing requirements and potentially lower liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- OTC Other tier companies may have difficulty raising capital.
- Delays in trade execution due to low volume.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Review the company's capitalization structure and ownership.
- Consult with a financial advisor to understand the risks involved.
- Check for any regulatory actions or legal proceedings against the company.
- Confirm the company's contact information and physical address.
- Established partnerships or collaborations with reputable companies.
- Experienced management team with a track record of success.
- Clear and transparent communication with investors.
- Independent audits of financial statements (if available).
- Active engagement with the investment community.
Syros Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Syros Pharmaceuticals, Inc. do?
Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene control medicines for cancer and monogenic diseases. Their pipeline includes Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III trials for myelodysplastic syndrome (MDS), SY-2101, an oral form of arsenic trioxide for acute promyelocytic leukemia (APL), and SY-5609, a CDK7 inhibitor in Phase I trials for advanced solid tumors. They aim to treat diseases by controlling genes and have collaborations with companies like Incyte to expand their research efforts.
What do analysts say about SYRS stock?
Analyst coverage of Syros Pharmaceuticals, Inc. is not available in the provided data. Therefore, I am unable to provide a summary of analyst consensus, key valuation metrics, or growth considerations. Without access to analyst reports and ratings, it is not possible to assess the market's perception of the company's prospects or provide insights into its potential investment value. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
What are the main risks for SYRS?
Syros Pharmaceuticals faces significant risks inherent to the biotechnology industry. Clinical trial failures for their drug candidates, particularly Tamibarotene, could severely impact the company's valuation. Regulatory hurdles and delays in obtaining drug approvals pose another substantial risk. Competition from larger, more established pharmaceutical companies with greater resources is also a concern. Furthermore, the company's reliance on external funding and its listing on the OTC market introduce additional financial and liquidity risks.
What are the key factors to evaluate for SYRS?
Syros Pharmaceuticals, Inc. (SYRS) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does SYRS data refresh on this page?
SYRS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SYRS's recent stock price performance?
Syros Pharmaceuticals, Inc. (SYRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary gene control technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYRS overvalued or undervalued right now?
Valuing Syros Pharmaceuticals, Inc. (SYRS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SYRS?
Before investing in Syros Pharmaceuticals, Inc. (SYRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data.
- OTC market data may be limited or outdated.